MX2021012769A - Anticuerpos bloqueadores cd73. - Google Patents

Anticuerpos bloqueadores cd73.

Info

Publication number
MX2021012769A
MX2021012769A MX2021012769A MX2021012769A MX2021012769A MX 2021012769 A MX2021012769 A MX 2021012769A MX 2021012769 A MX2021012769 A MX 2021012769A MX 2021012769 A MX2021012769 A MX 2021012769A MX 2021012769 A MX2021012769 A MX 2021012769A
Authority
MX
Mexico
Prior art keywords
compounds
blocking antibodies
antibodies
fragments
methods
Prior art date
Application number
MX2021012769A
Other languages
English (en)
Inventor
Laurent Gauthier
Ivan Perrot
Carine Paturel
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of MX2021012769A publication Critical patent/MX2021012769A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de los mismos que se unen e inhiben CD73. La invención también se refiere a células que producen tales compuestos; procedimientos para preparar dichos compuestos y anticuerpos, fragmentos, variantes y derivados de los mismos; composiciones farmacéuticas que lo comprenden; procedimientos de uso de los compuestos para diagnosticar, tratar o prevenir enfermedades, por ejemplo, cáncer.
MX2021012769A 2019-04-23 2020-04-20 Anticuerpos bloqueadores cd73. MX2021012769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837214P 2019-04-23 2019-04-23
PCT/EP2020/060955 WO2020216697A1 (en) 2019-04-23 2020-04-20 Cd73 blocking antibodies

Publications (1)

Publication Number Publication Date
MX2021012769A true MX2021012769A (es) 2021-11-18

Family

ID=70456747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012769A MX2021012769A (es) 2019-04-23 2020-04-20 Anticuerpos bloqueadores cd73.

Country Status (12)

Country Link
US (1) US20220041744A1 (es)
EP (1) EP3959239A1 (es)
JP (1) JP2022530404A (es)
KR (1) KR20220002959A (es)
CN (1) CN113784981A (es)
AU (1) AU2020260693A1 (es)
BR (1) BR112021021224A2 (es)
CA (1) CA3136698A1 (es)
IL (1) IL286997A (es)
MX (1) MX2021012769A (es)
SG (1) SG11202111106WA (es)
WO (1) WO2020216697A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204417B1 (en) 2014-10-10 2020-07-22 Innate Pharma Cd73 blockade
CA3074588A1 (en) * 2017-10-06 2019-04-11 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1513554B9 (en) 2002-05-30 2011-11-09 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
ES2639857T3 (es) 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
KR102049817B1 (ko) 2011-08-01 2019-12-02 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
EA035037B1 (ru) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
EP3204417B1 (en) * 2014-10-10 2020-07-22 Innate Pharma Cd73 blockade
KR20210023983A (ko) * 2018-06-18 2021-03-04 이나뜨 파르마 암을 치료하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
WO2020216697A1 (en) 2020-10-29
TW202104268A (zh) 2021-02-01
KR20220002959A (ko) 2022-01-07
CN113784981A (zh) 2021-12-10
AU2020260693A1 (en) 2021-10-28
JP2022530404A (ja) 2022-06-29
US20220041744A1 (en) 2022-02-10
EP3959239A1 (en) 2022-03-02
BR112021021224A2 (pt) 2021-12-21
CA3136698A1 (en) 2020-10-29
IL286997A (en) 2021-12-01
SG11202111106WA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2021012769A (es) Anticuerpos bloqueadores cd73.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2023002507A (es) Inhibidores de cd73.
MY200162A (en) Anti-gitr antibodies and uses thereof
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2015054600A3 (en) Glycan-interacting compounds and methods of use
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
MX2020012107A (es) Composiciones y procedimientos para el tratamiento del cancer.
NZ788133A (en) Cd73 inhibitors
MX2020007077A (es) Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.